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Abstract: The application of a cell-based growth inhibition on a library of skeletally different
glycomimetics allowed for the selection of a hexahydro-2H-furo[3,2-b][1,4]oxazine compound as
candidate inhibitors of MDA-MB-231 cell growth. Subsequent synthesis of analogue compounds
and preliminary biological studies validated the selection of a valuable hit compound with a novel
polyhydroxylated structure for the modulation of the breast carcinoma cell cycle mechanism.
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1. Introduction
In the last 25 years, target-based drug discovery has become a paradigm in both the
pharmaceutical industry and in academia. However, considering that it has proved hard to increase
the number of truly innovative new drugs, the interest towards phenotypic screening of large small
molecule libraries is growing fast [1,2]. In this context, Diversity-Oriented Synthesis (DOS) [3–5]
has proved to be very useful for the creation of high quality chemical libraries for early-stage drug
discovery programmes. In fact, it operates to generate the maximum skeletal and stereochemical
diversity by using forward synthetic analysis and complexity-generating reactions [6,7]. Recently,
natural product structures have proved to be optimal starting materials for DOS strategies [8–10],
thanks to their structural feasibility to generate compounds in the medicinally relevant chemical space
and following Lipinski’s rules [11]. In particular, carbohydrates can be exploited for the achievement
of skeletal diversity, taking advantage of their conformational constraints and the high density of
polar groups. Although the application of carbohydrates in traditional combinatorial chemistry
has been reported since the nineties [12–14], they remain rather underexplored in DOS strategies,
mainly because of their need for transitional protection/deprotection stages [15–21]. In this context,
we have reported the use of D-mannose in combination with glycine-derived aminoacetaldehyde
for the synthesis of an array of novel skeletally different polyhydroxylated nitrogen-containing
scaffolds [22]. The relevance of these compounds was attested by the widespread distribution of
polyhydroxylated nitrogen-containing natural products in plants and microorganisms (Figure 1).
In particular iminosugars [23–25], pyrrolidine [26,27], and pyrrolizidine alkaloids [28–32] occupy
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relevant positions in biomedical issues, for their potential in the development of new treatments
against cancer, infective diseases, diabetes, and metabolic disorders [33–35].
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particula ly succe sful for lead di covery in those complex disorders, such as cancer and neurological
and infective pathologies, where multiple targets are involved and/or physiopathological pathways
have yet to be discovered [40–42]. Just to give some examples, nifedipine, nimodipine, and other
calcium channel antagonists were actually discovered by the application of phenotypic screens in
search for compounds able to induce vasodilatation and blood pressure reduction [43,44]. In recent
years, different phenotypic screening methods have been developed, especially in the pharmaceutical
industries, were robotic and miniaturized technologies allow for rapidly screening large chemical
collections. Different phenotypes can be taken into account, such as the capability of killing pathogens
or cancer cells, or the modulation of autophagy and apoptosis, and cell cycle mechanisms are often
the most studied ones [45]. In particular, we reasoned to apply a cell-based phenotypic screening in
search of compounds inducing a significant cell growt arrest on MDA-MB-231 c ll lines. This cell
line is a simple model system for the udy of the triple-negative breast cancer (TNBC). Th s typ of
cancer s ows a major tendency toward early metastasis [46,47], and does not respond to ormonal
chemotherapy, as it lacks the three main molecular targets, the estrogen receptor (ER), the progesterone
receptor (PR), and the human epidermal growth factor receptor (HER-2/Neu) [48–50]. Therefore, the
development of new treatments against such type of cancer, which accounts for 15% of all type of
breast carcinomas, is highly needed. Although further research is still necessary, some preliminary
evidence about the ability of iminosugars to inhibit breast cancer cell growth has recently appeared
in the literature. In particular, different types of pyrrolidinic compounds have shown significant cell
growth inhibition in breast tumoral cell lines, such as T-470 [51] and MCF-7 line [52]. In addition,
iminosugar-ferrocene conjugates proved to inhibit MDA-MB-231 breast cancer cells proliferation [53].
In this work we present t e application of a MDA-MB-231 cell-based growth inhibition assay on a
library of skeletally different glycomimetics, and the follow-up synthesis of compounds containing the
same scaff ld as of selected molecules for preliminary biological studies aiming to ide tify a valuable
hit compound for the modulation of breast carcinoma cell cycle mechanism.
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2. Results and Discussion
The diversity-oriented synthesis of six polyhydroxylated nitrogen-containing scaffolds was
achieved by the combination of two building blocks, easily obtained from D-mannose, with
glycine-derived aminoacetaldehyde (Figure 2). Specifically, the synthesis of these compounds, as
previously described [22], was achieved following the build/couple/pair approach by applying
different synthetic strategies consisting of no more than four/five steps.
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shape, though still adhering to the substrate. This observation suggests that the effect of compound 
1 might induce a cell cycle slowdown and might not be related to any perturbation of the adhesive 
properties of the cell (Figure 4). In agreement with this, we found a dose-dependent cell growth 
inhibition, and we observed a significant reduction in cell proliferation at a concentration higher than 
3 μM (Figure 5), with an IC50 of 0.6 μM.  
Figure 2. Polyhydroxylated nitrogen-containing s l s derived from D-mannose and glycine-derived
amino cetaldehyde.
A first screening on MDA-MB-231 hu an t carcinoma cells was perfo med for the six
c mpounds at 10 µM concentration. After the first f treatment, no particular effects on cell growth
were observed (data not shown). Interestingly, after 48 h inc ti , lt gh a slightly induction
in cell proliferation was detected for compounds, 2, 3 and 6, we observed a significant reduction in
cell proliferation following the treatment with compound 1, containing the hexahydro-2H-furo[3,2-b]
[1,4]oxazine scaffold (p < 0.05), with a 40% inhibition of cell growth (Figure 3). A similar range of
inhibition was found by others [54].
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corresponding standard deviations values. Student’s t test was used to evaluate the data significance,
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Examination of cell morphology reveals essential information regarding the healthy status of a
cell population. This inspection indicated that, after 48 h incubation, MDA-MB-231 cells were reduced
in number, and part of the cell population showed a regular appearance, while part exhibited a round
shape, though still adhering to the substrate. This observation suggests that the effect of compound
1 might induce a cell cycle slowdown and might not be related to any perturbation of the adhesive
properties of the cell (Figure 4). In agreement with this, we found a dose-dependent cell growth
inhibition, and we observed a significant reduction in cell proliferation at a concentration higher than
3 µM (Figure 5), with an IC50 of 0.6 µM.Molecules 2016, 21, 405 4 of 17 
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Figure 4. Control cells after 48 h (left), and cells after 48 h of incubation with compound 1 at 10 µM
concentration (right).
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In order to study and improve the activity of this compound, a pool of hexahydro-2H-furo[3,2-b]
[1,4]oxazine compounds with different polyhydroxylated chains, stereochemistry, and amine
functionalities, were synthetized following the two-step process s r rte in Scheme 1 and Table 1.
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The reaction of the sugar derivatives 7–10 with glycine-derived amino acetaldehyde by formation 
of the glycosyl amine and the direct N-acylation of the crude hemiaminal coupling intermediates resulted 
in the achievement of compounds 11–16. Then, under acid-catalyzed trans-acetalization conditions, the 
reaction of the C-3a hydroxyl group of the intermediate with the dimethylacetal carbon atom, led to 
the synthesis of the corresponding bicyclic compounds 17–20. In this way, as reported in Table 1, the 
compounds with different polyhydroxylated chains and different stereochemistry were obtained 
starting from the appropriate furanosidic monosaccharide. Specifically, from 2,3-O-isopropylidene-
D-ribofuranose (7) and 2,3-O-isopropylidene-D-lyxofuranose (8) the corresponding Fmoc-protected 
intermediates 11α/11β and 12α/12β were obtained with a clean conversion and a successful separation 
of the two anomers, similarly to what obtained from 2,3:5,6-O-di-isopropylidene-D-mannose 10, as 
reported [22]. The assignment of the configuration of the anomers was established by analysing the 
coupling constants between the protons of the CH2N-moiety of the corresponding deprotected mannose-
derived coupling intermediates, which are more stable and achievable by column chromatography, 
according to data reported in the literature for similar amino-α-D-mannofuranoses [55].  
The preferred anomer of compounds 11–16 were found to be the α-anomer, even though starting 
from lyxose the ratio between the two anomeric compounds 12 became approximately 1:1 (Table 1, 
entry 2). The instability of the erythrose-derived coupling intermediate was evinced by the low yield of 
the reaction and in the achievement of only the most stable α-anomer product 13α (Table 1, entry 3). 
Upon treating both the anomers of the coupling intermediates under neat TFA conditions, the 
corresponding bicyclic cis-fused scaffolds 17–20 were obtained, even if in less yield as compared to 
the mannose-derived bicycle 1 (entry 4). In all cases, the same scaffold was achieved from both the 
anomers in similar yields as a consequence of a thermodynamic equilibration of N-Fmoc hemiaminal 
intermediate species under the acidic treatment [56]. 
The cis-fusion was evinced by NOESY1D experiments of the fully acetylated compound 21 
(Scheme 2 and Figure 6). The same cis-fusion was evinced for the other scaffolds thanks to the diagnostic 
signal of the bridgehead protons which appeared as singlets in a diagnostic and unambiguous region 
of 1H-NMR spectrum between 5.70 and 4.70 ppm. In all cases only the endo anomer was recovered, 
which is the most stable for stereoelectronic effects.  
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intermediates 11α/11β and 12α/12β were obtained with a clean conversion and a successful separation 
of the two anomers, similarly to what obtained from 2,3:5,6-O-di-isopropylidene-D-mannose 10, as 
reported [22]. The assignment of the configuration of the anomers was established by analysing the 
coupling constants between the protons of the CH2N-moiety of the corresponding deprotected mannose-
derived coupling intermediates, which are more stable and achievable by column chromatography, 
according to data reported in the literature for similar amino-α-D-mannofuranoses [55].  
The preferred anomer of compounds 11–16 were found to be the α-anomer, even though starting 
from lyxose the ratio between the two anomeric compounds 12 became approximately 1:1 (Table 1, 
entry 2). The instability of the erythrose-derived coupling intermediate was evinced by the low yield of 
the reaction and in the achievement of only the most stable α-anomer product 13α (Table 1, entry 3). 
Upon treating both the anomers of the coupling intermediates under neat TFA conditions, the 
corresponding bicyclic cis-fused scaffolds 17–20 were obtained, even if in less yield as compared to 
the mannose-derived bicycle 1 (entry 4). In all cases, the same scaffold was achieved from both the 
anomers in similar yields as a consequence of a thermodynamic equilibration of N-Fmoc hemiaminal 
intermediate species under the acidic treatment [56]. 
The cis-fusion was evinced by NOESY1D experiments of the fully acetylated compound 21 
(Scheme 2 and Figure 6). The same cis-fusion was evinced for the other scaffolds thanks to the diagnostic 
signal of the bridgehead protons which appeared as singlets in a diagnostic and unambiguous region 
of 1H-NMR spectrum between 5.70 and 4.70 ppm. In all cases only the endo anomer was recovered, 
which is the most stable for stereoelectronic effects.  
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The reaction of the sugar derivatives 7–10 with glycine-derived amino acetaldehyde by formation 
of the glycosyl amine and the direct N-acylation of the crude hemiaminal coupling intermediates resulted 
in the achievement of compounds 11–16. Then, under acid-catalyzed trans-acetalization conditions, the 
reaction of the C-3a hydroxyl group of the intermediate with the dimethylacetal carbon atom, led to 
the synthesis of the corresponding bicyclic compounds 17–20. In this way, as reported in Table 1, the 
compounds with different polyhydroxylated chains and different stereochemistry were obtained 
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D-ribofuranose (7) and 2,3-O-isopropylidene-D-lyxofuranose (8) the corresponding Fmoc-protected 
intermediates 11α/11β and 12α/12β were obtained with a clean conversion and a successful separation 
of the two anomers, similarly to what obtained from 2,3:5,6-O-di-isopropylidene-D-mannose 10, as 
reported [22]. The assignment of the configuration of the anomers was established by analysing the 
coupling constants between the protons of the CH2N-moiety of the corresponding deprotected mannose-
derived coupling intermediates, which are more stable and achievable by column chromatography, 
according to data reported in the literature for similar amino-α-D-mannofuranoses [55].  
The preferred anomer of compounds 11–16 were found to be the α-anomer, even though starting 
from lyxose the ratio between the two anomeric compounds 12 became approximately 1:1 (Table 1, 
entry 2). The instability of the erythrose-derived coupling intermediate was evinced by the low yield of 
the reaction and in the achievement of only the most stable α-anomer product 13α (Table 1, entry 3). 
Upon treating both the anomers of the coupling intermediates under neat TFA conditions, the 
corresponding bicyclic cis-fused scaffolds 17–20 were obtained, even if in less yield as compared to 
the mannose-derived bicycle 1 (entry 4). In all cases, the same scaffold was achieved from both the 
anomers in similar yields as a consequence of a thermodynamic equilibration of N-Fmoc hemiaminal 
intermediate species under the acidic treatment [56]. 
The cis-fusion was evinced by NOESY1D experiments of the fully acetylated compound 21 
(Scheme 2 and Figure 6). The same cis-fusion was evinced for the other scaffolds thanks to the diagnostic 
signal of the bridgehead protons which appeared as singlets in a diagnostic and unambiguous region 
of 1H-NMR spectrum between 5.70 and 4.70 ppm. In all cases only the endo anomer was recovered, 
which is the most stable for stereoelectronic effects.  
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The reaction of the sugar derivatives 7–10 with glycine-derived amino acetaldehyde by formation 
of the glycosyl a ine and the direct N-acylation of the crude hemiaminal coupling intermediates resulted 
in the achievement of compounds 11–16. Then, under acid-catalyzed trans-acetalization conditions, the 
reaction of the C-3a hydroxyl group of the inter ediate with the dimethylacetal carbon atom, led to 
the synthesis of the corresponding bicyclic compounds 17–20. In this way, as reported in Table 1, the 
compounds with different polyhydroxylated chains and different stereoche istry were obtained 
starting from the appropriate furanosidic monosaccharide. Specifically, from 2,3-O-isopropylidene-
D-ribofuranose (7) and 2,3-O-isopropylidene-D-lyxofuranose (8) the corresponding Fmoc-protected 
intermediates 11α/11β and 12α/12β ere obtained with a clean conversion and a successful separation 
of the two anomers, similarly to what obtained from 2,3:5,6-O-di-isopropylidene-D-mannose 10, as 
reported [22]. The assignment of the configuration of the anomers was established by analysing the 
coupling constants between the protons of the CH2N-moiety of the corresponding deprotected annose-
derived coupling intermediates, which are more stable and achievable by column chromatography, 
according to data reported in the literature for similar amino-α-D-mannofuranoses [55].  
The preferred anomer of compounds 11–16 were found to be the α-anomer, even though starting 
from lyxose the ratio between the two anomeric compounds 12 became approximately 1:1 (Table 1, 
entry 2). The instability of the erythrose-derived coupling intermediate was evinced by the low yield of 
the reaction and in the achievement of only the most stable α-anomer product 13α (Table 1, entry 3). 
Upon treating both the anomers of the coupling intermediates under neat TFA conditions, the 
corresponding bicyclic cis-fused scaffolds 17–20 were obtained, even if in less yield as compared to 
the annose-derived bicycle 1 (entry 4). In all cases, the sa e scaffold was achieved from both the 
anomers in similar yields as a consequence of a thermodynamic equilibration of N-Fmoc hemiaminal 
intermediate species under the acidic treatment [56]. 
The cis-fusion was evinced by NOESY1D experiments of the fully acetylated compound 21 
(Scheme 2 and Figure 6). The same cis-fusion was evinced for the other scaffolds thanks to the diagnostic 
signal of the bridgehead protons which appeared as singlets in a diagnostic and una biguous region 
of 1H-NMR spectrum between 5.70 and 4.70 ppm. In all cases only the endo anomer was recovered, 
which is the most stable for stereoelectronic effects.  
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The reaction of the sugar deri atives 7–10 with glycin -d rived amino cetaldehyde by formation 
of the glycosyl ami e and the direct N-acylation of the crude he aminal coupl g int rmediat  resulted 
in the achievement f compounds 1–16. The , under a id-catalyzed tr ns- cet l zation conditions, the 
reacti n of the C-3a hydroxyl group of the intermediate with the dimethylacet l carbon atom, led to 
the synthesis of the co respo ding bicyclic compounds 17–20. In this w y, as reported in Table 1, the 
compounds with di ferent polyhydroxylated chains and di ferent stereochemistry were obtained 
starting from the a opriate furanosidic monosa charide. Specifically, from 2,3-O-is ropylidene-
D-ribofuranose (7) and 2,3-O-is ropylidene-D-lyxofuranose (8) the co respo ding Fmoc-protected 
intermediates α/ 1β and 12α/12β were obtained with a clean conversion and a su ce sful separation 
of the two anomers, similarly to what obtained from 2 3:5,6-O-di-is ropylidene-D-ma nose 10, as 
reported [ 2]. The a signment of the configurati n of the anomers was established by analysing the 
coupling constants b tw en the prot ns of the CH2N-moiety of the co respo ding deprotected ma nose-
d rived coupling int rmediates, which are more stable and achieva le by column chromatography, 
a cording to data reported in th  literature for similar amino-α-D-ma nofuranoses [ 5].  
Th  prefe red anomer f compounds 1–16 were found to b the α-anomer, even though starting 
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the a nos -derived bicycle 1 (entry 4). In all cases, the sa e sca fold was achieved fro  both the 
ano ers n similar yields as a cons qu nce of a thermodynamic equilibration of N-Fmoc he iaminal 
intermediate species under the a idic treatment [56]. 
The ci -fusion was evinced by NOESY1D xperiments of the fully acetylated compound 21 
(Scheme 2 and Figure 6). The same ci -fusion was evinced for the other sca folds thanks to the diagnostic 
signal of the bridgehead protons which a peared as singlets in  diagnostic and unambiguous region 
of 1H-NMR spectrum b tw en 5.70 and 4.70 pm. In all cases only the endo anomer was recovered, 
wh ch is the most stable for stereoelectronic e fects.  
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CH2N-moiety f the corresponding dep o ected annose-derived coupli g i term diates, which are
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more stable and achievable by column chromatography, according to data reported in the literature for
similar amino-α-D-mannofuranoses [55].
The preferred anomer of compounds 11–16 were found to be the α-anomer, even though starting
from lyxose the ratio between the two anomeric compounds 12 became approximately 1:1 (Table 1,
entry 2). The instability of the erythrose-derived coupling intermediate was evinced by the low yield
of the reaction and in the achievement of only the most stable α-anomer product 13α (Table 1, entry 3).
Upon treating both the anomers of the coupling intermediates under neat TFA conditions, the
corresponding bicyclic cis-fused scaffolds 17–20 were obtained, even if in less yield as compared to
the mannose-derived bicycle 1 (entry 4). In all cases, the same scaffold was achieved from both the
anomers in similar yields as a consequence of a thermodynamic equilibration of N-Fmoc hemiaminal
intermediate species under the acidic treatment [56].
The cis-fusion was evinced by NOESY1D experiments of the fully acetylated compound 21
(Scheme 2 and Figure 6). The same cis-fusion was evinced for the other scaffolds thanks to the diagnostic
signal of the bridgehead protons which appeared as singlets in a diagnostic and unambiguous region
of 1H-NMR spectrum between 5.70 and 4.70 ppm. In all cases only the endo anomer was recovered,
which is the most stable for stereoelectronic effects.Molecules 2016, 21, 405 6 of 17 
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resulted in a clean cyclization to the final product, benzoyl analogues (15α/15β) failed to give the 
corresponding bicyclic compound, as a consequence of the reduced stability of the N-acyl moiety.  
The reaction of the hemiaminal intermediate with sulfonyl chloride was not possible at all. 
However, in order to explore the possibility of introducing a different moiety linked to the amine and 
studying their biological effect, the tosyl derivative 23 was obtained from the corresponding per-O-
acetylated N-deprotected 22 (Scheme 2) subsequent to Fmoc deprotection of 21. 
In order to assess the stability of this class of bicyclic compounds based on the hexahydro-2H-
furo[3,2-b][1,4]oxazine scaffold concerning the hemiaminal moiety under acidic conditions, a study 
by HPLC analysis was performed on 18 as a representative compound in MeOH and acetonitrile as 
solvents and in the presence of 1 M HCl, after 1 h and 24 h. In all cases, neither the formation of by-
products nor the reduction of peak intensity was evinced, as compared to benzophenone as an 
internal standard (see Supplementary Materials for HPLC data). 
These new compounds were tested for their inhibition activity at 10 μM concentration after 48 h 
of incubation on the same MDA-MB-231 cell line. As reported in Table 2, none of these compounds 
proved to be as interesting as 1, revealing a specific structural requirement for an optimal inhibition 
profile. The importance of the number hydroxyl groups and their stereochemistry for the activity was 
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1, 20, and 23, all possessing similar scaffold and polyhydroxylated tail, and differing by the Fmoc, Cbz 
and tosyl group at the nitrogen atom, respectively. All in all, the biological data suggested a specific 
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change in the structure or appendage of the lead compound 1 caused a drop in the biological activity. 
We investigated the effect of compound 1 in cell viability using the WST-1 tetrazolium salt assay. 
The stable tetrazolium salt WST-1 is cleaved to a soluble formazan by a mechanism that is largely 
dependent on the glycolytic production of NAD(P)H in viable cells, thus, the amount of formazan 
dye produced directly correlates with the number of metabolically active cells. We tested different 
concentrations of compound 1, and we found that the number of dead cell was not significantly 
different as compared to the control (Figure 7). Moreover, we investigated the effect of compound 1 
on MDA-MB-231 cell cycle. We found that, starting from 10 μM concentration, this compound clearly 
induced a significant arrest of MDA-MB-231 cell cycle (Figure 8, upper panel). The effect on cell 
apoptosis was evaluated in the entire exposed cell population. As mentioned before, no significative 
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Figure 6. S lected nOe contact f OESY1D spectra of 21.
The derivatization of the unstable he ia i al coupling intermediate was possible only using
benzoyl chloride (entry 5) and chloroformates (entries 4 and 6). However, even if the use of
chloroformate resulted in a clean cyclization to he final product, benzoyl analogues (15α/15β)
failed to give the corresponding bicyclic compound, as a consequence of the reduced stability of the
N-acyl moiety.
The reaction of the hemiaminal intermediate with sulfonyl chloride was not possible at all.
However, in order to explore the possibility of introducing a different moiety linked to the amine
and studying their biological effect, the tosyl derivative 23 was obtained from the corresponding
per-O-acetylated N-deprotected 22 (Scheme 2) subsequent to Fmoc deprotection of 21.
In order to assess the stability of this class of bicyclic compounds based on the hexahydro-2H-
furo[3,2-b][1,4]oxazine scaffold concerning the hemiaminal moiety under acidic conditions, a study
by HPLC analysis was performed on 18 as a representative compound in MeOH and acetonitrile as
solvents a d in the presence of 1 M HCl, after 1 h and 24 h. In all cases, neither th f i of
by-produc s nor the reduction of peak i tensity was evinced, compared to benzophenone as an
internal stan ard (see Supplementary Materials for PLC data).
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These new compounds were tested for their inhibition activity at 10 µM concentration after 48 h
of incubation on the same MDA-MB-231 cell line. As reported in Table 2, none of these compounds
proved to be as interesting as 1, revealing a specific structural requirement for an optimal inhibition
profile. The importance of the number hydroxyl groups and their stereochemistry for the activity
was evinced by comparing the inhibition activities of Fmoc-derivatives 1 and 17–19, and those of 1
and the corresponding fully acetylated derivative 21. Finally, an indication of the importance of the
functionalization of the hemiaminal nitrogen atom was shown by comparing the inhibition activities of
1, 20, and 23, all possessing similar scaffold and polyhydroxylated tail, and differing by the Fmoc, Cbz
and tosyl group at the nitrogen atom, respectively. All in all, the biological data suggested a specific
effect of the bicyclic compounds towards cell growth inhibition of MDA-MB-231 cells, as any small
change in the structure or appendage of the lead compound 1 caused a drop in the biological activity.
Table 2. Cell growth inhibition of MDA-MB-231 cell line at 10 µM concentration after 48 h of incubation.
Compoud Structure % Inhibition a
1
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effect on cell adhesion was found, however, after the 48 h treatment, the very few cells present in the 
supernatant and the adherent cells were grouped together and no differences were observed between 
the diverse cell treatments in terms of apoptosis (Figure 8, lower panel). Overall, it is possible to 
assume that the growth inhibition induced by compound 1 on MDA-MB-231 cells, might be 
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We investigated the effect of compound 1 in cell viability using the WST-1 tetrazolium salt assay.
The stable tetrazolium salt WST-1 is cleaved to a soluble formazan by a mechanism that is largely
dependent on the glycolytic production of NAD(P)H in viable cells, thus, the amount of formazan
dye produced directly correlates with the number of metabolically active cells. We tested different
concentrations of compound 1, and we found that the number of dead cell was not significantly
different as compared to the control (Figure 7). Moreover, we investigated the effect of compound 1 on
MDA-MB-231 cell cycle. We found that, starting from 10 µM concentration, this compound clearly
induced a significant arrest of MDA-MB-231 cell cycle (Figure 8, upper panel). The effect on cell
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apoptosis was evaluated in the entire exposed cell population. As mentioned before, no significative
effect on cell adhesion was found, however, after the 48 h treatment, the very few cells present in the
supernatant and the adherent cells were grouped together and no differences were observed between
the diverse cell treatments in terms of apoptosis (Figure 8, lower panel). Overall, it is possible to
assume that the growth inhibition induced by compound 1 on MDA-MB-231 cells, might be correlated
to a cytostatic effect, rather than to a cytotoxic one. Thus, the exploration of the fine mechanisms that
regulate the cell cycle will be performed in future to identify the protein target of compound 1, and
future experiments on non-transformed epithelial cells will be performed to ensure the selectivity and
specificity of the compounds [57].
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The identification of the target responsible for the observed phenotype, above the many different
growth factor signals and cyclin-dependent kinases will shed light in the understanding of tumor
cell growth and progression [58,59]. Moreover, further investigations will be attempted in view to
characterize the signaling pathways underlying the biological effect [60–62], particularly investigating
the role of caspases and the modulation of their phosphorylation [60,63,64].
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3. Materials and Methods
3.1. General Methods
Analytical grade solvents and commercially available reagents were used without further
purification. Flash column chromatography (FCC) purifications were performed manually using
glass columns with Merck silica gel (0.040–0.063 mm, Merck, Darmstad, Germany), or using the Isolera
system (Biotage, Uppsala, Sweden) and SNAP silica cartridges. TLC analyses were performed on
Merck silica gel 60 F254 plates. 1H-NMR and 13C-NMR spectra were recorded on a Mercury 400
(1H: 400 MHz, 13C: 100 MHz), or a Gemini 200 (1H: 200 MHz, 13C: 50 MHz) instrument (Varian,
Palo Alto, CA, USA). HSQC experiments were carried out to define the multiplicity of 13C signals.
All chemical shifts are reported in parts per million (δ) referenced to residual nondeuterated solvent.
Data are reported as follows: chemical shifts, multiplicity (br = broad, s = singlet, d = doublet, t = triplet,
q = quartet, m = multiplet; coupling constant(s) in Hz; integration). ESI mass spectra were carried out
on a ion-trap double quadrupole mass spectrometer using electrospray (ES+) ionization techniques,
and a normalized collision energy within the range of 25−32 eV for MSMS experiments. IR spectra
were recorded with a FTIR-1600 spectrophotometer (Perkin-Elmer, Waltham, MA, USA). Elemental
analyses were performed on a Perkin Elmer 240 C, H, N analyzer. Optical rotation measurements were
performed on a DIP-370 polarimeter (JASCO Easton, MD, USA) and are given in 10−1 deg·cm2·g−1.
3.2. (9H-Fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aR,4S,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (11α) and (9H-Fluoren-9-yl)-methyl-(2,2-dimethoxyethyl)-
((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (11β)
To a solution of 2,3-O-isopropylidene-D-ribofuranose (7, 800 mg, 4.20 mmol) [65] and
2,2-dimethoxyethylamine (0.55 mL, 5.04 mmol) in MeOH (24 mL), MgSO4 (1.010 g, 8.40 mmol) was
added and the reaction mixture was left stirring at reflux for 48 h. MgSO4 was then removed by
filtration through Celite and the filtrate was concentrated under vacuum to give the crude hemiaminal
intermediate, which was unstable under silica gel column chromatography conditions. The crude
compound was then dissolved in dioxane (5 mL) and in a solution of NaHCO3 (705 mg, 8.40 mmol)
in water (10 mL). The mixture was cooled to 0 ◦C, then a solution of Fmoc-Cl (1.090 g, 8.40 mmol) in
dioxane (5 mL) was added slowly and the resulting suspension was left reacting at room temperature
for 24 h under a nitrogen atmosphere, then it was diluted with EtOAc (30 mL). The organic phase was
washed with 1M HCl solution, brine, and dried over anhydrous Na2SO4. After solvent evaporation, the
crude oil was purified by flash chromatography (EtOAc/Pet. ether = 1:2; Rf 11β = 0.31, Rf 11α = 0.14),
thus affording compound 11β (418 mg, 0.84 mmol, 20%) and compound 11α (796 mg, 1.59 mmol,
38%), both as colorless oils.
11α: [α]20D = −50.6 (c 1.4, CHCl3). 1H-NMR (400 MHz, CDCl3) δ 7.68 (d, J = 7.4 Hz, 2H), 7.64–7.57 (m,
2H), 7.32 (pt, J = 7.3 Hz, 2H), 7.29 (pt, J = 7.4 Hz, 2H), 5.77 (br s, 0.5H), 5.20 (br s, 0.5H), 4.82–4.41 (m,
5H), 4.27 (pt, J = 5.2 Hz, 1H), 4.18 (br s, 0.5H), 3.85 (br s, 0.5H), 3.69–3.54 (m, 3H), 3.43–3.37 (m, 1H),
3.20 (s, 6H), 2.05 (br s, 1H, OH), 1.41–1.38 (m, 3H), 1.24–1.18 (m, 3H). 13C-NMR (100 MHz, CDCl3)
mixture of rotamers: δ 156.0 (s), 143.9 (s, 2C), 141.3 (s, 2C), 127.6 (d, 2C), 127.1 (d, 2C), 124.9 (d, 2C),
119.8 (d, 2C), 112.7 (s), 103.4 e 102.5 (d), 95.0 (d), 86.2 (d), 82.6 (d), 80.0 (d), 67.2 and 67.0 (t), 63.2 (t),
53.4 (q, 2C), 47.2 (d), 45.1 and 45.0 (t), 26.0 (q), 24.1 (q). MS (ESI) m/z (%): 521.60 [(M + Na)+, 100]. IR
(CDCl3): ν = 3608, 2940, 1701, 1452, 1384, 1215 cm−1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 6.66; N,
2.80. Found: C, 65.22; H, 6.71; N, 2.63.
11β: [α]19D =−12.2 (c 1.3, CHCl3). 1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.75 (d, J = 7.5 Hz,
2H), 7.58 (d, J = 7.6 Hz, 2H), 7.38 (pt, J = 7.0 Hz, 2H), 7.31 (pt, J = 7.4 Hz, 2H), 4.79 (br s, 1.5H), 4.60 (d,
J = 7.4 Hz, 2H), 4.38 (s, 0.5H), 4.21 (pt, J = 5.2 Hz, 1H), 4.02 (br s, 2H), 3.81 (d, J = 12.7 Hz, 1H), 3.66 (d,
J = 7.4 Hz, 1H), 3.45–3.08 (m, 4H), 3.23 (s, 6H), 1.51 (s, 3H), 1.30 (s, 3H). 13C-NMR (100 MHz, CDCl3)
mixture of rotamers: δ 155.4 (s), 143.6 (s, 2C), 141.4 and 141.3 (s, 2C), 127.8 (d, 2C), 127.2 and 127.1 (d,
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2C), 124.8 (d, 2C), 120.0 (d, 2C), 112.5 (s), 103.6 (d), 96.5 (d), 88.0 (d), 85.5 (d), 79.8 (d), 67.8 (t), 63.9 (t),
56.9 and 55.2 (q, 2C), 50.7 (t), 47.2 (d), 27.3 (q), 25.4 (q). MS (ESI) m/z (%): 521.88 [(M + Na)+, 100]. IR
(CDCl3): ν = 3590, 2939, 1706, 1472, 1386, 1261 cm−1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 6.66; N,
2.80. Found: C, 65.26; H, 6.74; N, 2.61.
3.3. (9H-Fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aS,4S,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetra-
hydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (12α) and (9H-Fluoren-9-yl)-methyl-(2,2-dimethoxyethyl)-
((3aS,4R,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (12β)
Compounds 12α/12β were synthesized from 2,3-O-isopropylidene-D-lyxofuranose 8 [66,67]
(826 mg, 4.34 mmol) as reported for 11α/11β. After solvent evaporation, the crude oil was purified by
flash chromatography (EtOAc/Pet. ether = 1:1; Rf 12β = 0.52; Rf 12α = 0.17), thus affording compound
12β (776 mg, 1.55 mmol, 31%) and compound 12α (816 mg, 1.63 mmol, 32%), both as white foam.
12α: (α]21D = +50.4 (c 1.3, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers δ 7.68 (d, J = 7.2 Hz,
2H), 7.59–7.41 (m, 2H), 7.32 (pt, J = 7.2 Hz, 2H), 7.26–7.22 (m, 2H), 5.56 (br s, 0.5H), 5.31 (br s, 0.5H),
4.97 (br s, 0.5H), 4.70–4.37 (m, 4.5H), 4.19 (pt, J = 5.2 Hz, 1H), 3.90–3.63 (m, 2H), 3.46–3.40 (m, 1H), 3.38
(s, 6H), 3.25–3.19 (m, 2H), 2.15 (br s, 1H, OH), 1.36–1.13 (m, 6H). 13C-NMR (100 MHz, CDCl3) mixture
of rotamers: δ 155.7 (s), 143.9 (s, 2C), 141.3 (s, 2C), 127.8 and 127.7 (d, 2C), 127.2 and 127.1 (d, 2C), 125.0
and 124.6 (d, 2C), 120.0 and 119.8 (d, 2C), 112.7 (s), 103.4 e 102.6 (d), 86.8 (d), 85.0 (d), 79.9 and 79.5 (d),
78.2 (d), 68.1 and 67.5 (t), 60.6 (t), 52.5 (q), 50.7 (q), 47.2 (d), 45.5 (t), 25.5 and 25.1 (q), 23.9 and 23.7 (q).
MS (ESI) m/z (%): 522.28 [(M + Na)+, 100]. IR (CDCl3): ν = 3075, 2939, 1706, 1261 cm−1. Anal. Calcd.
for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C, 65.23; H, 6.70; N, 2.64.
12β: (α]22D = +4.1 (c 1.3, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.76 (d, J = 7.4 Hz,
2H), 7.59 (d, J = 7.2 Hz, 2H), 7.40 (pt, J = 7.3 Hz, 2H), 7.33 (pt, J = 7.3 Hz, 2H), 5.06–4.80 (m, 4H),
4.60–4.45 (m, 3H), 4.21 (pt, J = 5.2 Hz, 1H), 4.05–4.02 (m, 1H), 3.90–3.78 (m, 3H), 3.26 (s, 6H), 2.06 (br
s, 1H, OH), 1.46 (m, 3H), 1.30 (s, 3H). 13C-NMR (100 MHz, CDCl3) mixture of rotamers: δ 155.8 (s),
143.6 (s, 2C), 141.4 and 141.3 (s, 2C), 127.8 (d, 2C), 127.2 (d, 2C), 124.7 (d, 2C), 120.0 (d, 2C), 112.4 (s),
103.5 (d), 96.4 (d), 85.8 (d), 83.6 (d), 82.4 (d), 66.7 (t), 62.0 (t), 55.2 (q, 2C), 50.4 (t), 47.3 (d), 26.2 and 25.9
(q), 24.3 (q). MS (ESI) m/z (%): 522.28 [(M + Na)+, 100]. IR (CDCl3): ν = 3567, 2901, 1703, 1448, 1354,
1216 cm−1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C, 65.26; H, 6.78; N, 2.60.
3.4. (9H-Fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aS,4S,6aS)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]-
dioxol-4-yl)carbamate (13α)
Compound 13α was obtained from 2,3-O-isopropylidene-L-erythrofuranose (9, 920 mg,
5.74 mmol) as a single product with the same procedure reported for 11α/11β. After solvent
evaporation, the crude oil was purified by flash chromatography (EtOAc/Petr. et. = 1:3; Rf 13α = 0.29),
thus affording the α-anomer 13α (834 mg, 1.78 mmol, 32%) as a colourless oil. Anomer β was recovered
only in traces (<10 mg). (α]22D = +72.9 (c 1.4, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers:
δ 7.76 (d, J = 7.5 Hz, 2H), 7.69–7.58 (m, 2H), 7.40 (pt, J = 7.4 Hz, 2H), 7.34–7.29 (m, 2H), 5.32 (br s, 1H),
4.73–4.39 (m, 5H), 4.28 (t, J = 5.9 Hz, 1H), 4.10–3.99 (m, 1.5H), 3.81 (br s, 0.5H), 3.56 (br s, 2H), 3.30
(s, 6H), 1.47–1.24 (m, 6H). 13C-NMR (100 MHz, CDCl3) mixture of rotamers: δ 155.8 (s), 144.0 and 143.9
(s, 2C), 141.3 (s, 2C), 127.7 and 127.6 (d, 2C), 127.2 and 127.1 (d, 2C), 124.9 (d, 2C), 119.8 (d, 2C), 112.4
(s), 103.5 (d), 87.8 (d), 79.3 (d), 78.8 (d), 69.7 (t), 67.2 (t), 53.5 (q, 2C), 47.2 (d), 45.4 (t), 25.8 (q), 24.1 (q).
MS (ESI) m/z (%): 492.36 [(M + Na)+, 100]. IR (CDCl3): ν = 2939, 1703, 1451, 1216 cm−1. Anal. Calcd.
for C26H31NO7: C, 66.51; H, 6.65; N, 2.98. Found: C, 66.80; H, 6.71; N, 2.89.
3.5. N-(2,2-Dimethoxyethyl)-N-((3aS,4S,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetra-
hydrofuro[3,4-d][1,3]dioxol-4-yl)benzamide (15α) and N-(2,2-Dimethoxyethyl)-N-((3aS,4R,6R,6aS)-6-((R)-
2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)benzamide (15β)
To the crude hemiaminal coupling intermediate, prepared from 2,3:5,6-O-di-isopropylidene-D-
mannose 10 (60 mg, 0.23 mmol) as reported for 11α/11β, and Et3N (70 µL, 0.51 mmol) in dry THF
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(0.5 mL), a solution of benzoyl chloride (31 µL, 0.27 mmol) in dry THF (0.5 mL) was added dropwise
at 0◦C. The mixture was allowed to reach room temperature and was left stirring for two days under
a nitrogen atmosphere. Successively the mixture was washed with a saturated solution of NaHCO3,
a solution of 1N HCl and brine. After solvent evaporation, the crude oil was purified by flash
chromatography (EtOAc/Pet. ether = 1:1; Rf 15β = 0.61, Rf 15α = 0.39), thus affording compound 15β
(35 mg, 0.08 mmol, 33%) and compound 15α (50 mg, 0.11 mmol, 49%), both as colorless oils.
15α: (α]23D = +63.0 (c 1.0, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.48–7.38 (m, 5H),
4.71 (br s, 2H), 4.43 (q, J = 5.8 Hz, 1H), 4.13–4.09 (m, 3H), 3.66–3.61 (m, 3H), 3.43 (s, 1H), 3.28 (br s, 3H),
1.52 (s, 3H), 1.44 (s, 3H), 1.38 (s, 3H), 1.32 (s, 3H). 13C-NMR (100 MHz, CDCl3) mixture of rotamers: δ
172.1 (s), 136.0 and 132.8 (s), 131.2 and 129.6 (d), 128.2 and 128.0 (d, 2C), 126.8 and 126.6 (d, 2C), 112.5
(s), 108.9 (s), 103.4 and 102.4 (d), 87.2 and 79.4 (d), 78.8 (d), 78.2 (d), 77.4 (d), 72.7 (d), 66.3 (t), 54.3 and
53.6 (q), 53.5 and 53.4 (q), 47.2 and 41.2 (t), 26.6 (q), 25.4 (q), 24.9 (q), 23.7 (q). MS (ESI) m/z (%): 474.20
[(M + Na)+, 100], 924.59 [(2M + Na)+, 16]. IR (CDCl3): ν = 3019, 1626, 1521, 1423, 1216, 1046 cm−1.
Anal. Calcd. for C23H33NO8: C, 61.18; H, 7.37; N, 3.10. Found: C, 61.43; H, 7.45; N, 3.00.
15β: (α]23D = +8.0 (c 0.7, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.41–7.36 (m, 5H),
5.20 (d, J = 7.0 Hz, 2H), 5.01 (br s, 1H), 4.54 (br s, 2H), 4.32 (q, J = 5.9 Hz, 1H), 4.06 (dd, J = 8.1, 6.3 Hz,
1H), 3.99 (dd, J = 8.1, 5.2 Hz, 1H), 3.57 (dd, J = 14.6, 5.6, 1H), 3.38 (s, 3H), 3.31 (s, 3H), 3.38–3.22 (m, 1H),
1.43 (s, 6H), 1.36 (s, 3H), 1.32 (s, 3H). 13C-NMR (100 MHz, CDCl3) major rotamer: δ 168.6 (s), 135.8 (s),
130.1 (d), 128.4 (d, 2C), 127.4 (d, 2C), 108.9 (s), 103.8 (s), 95.0 (d), 85.7 (d), 85.1 (d), 84.9 (d), 81.5 (d), 74.0
(d), 66.5 (t), 56.1 (q, 2C), 48.4 (t), 26.9 (q, 2C), 26.2 (q), 25.2 (q). MS (ESI) m/z (%): 474.19 [(M + Na)+,
100]. IR (CDCl3): ν = 3016, 1625, 1520, 1427, 1220, 1041 cm−1. Anal. Calcd. for C23H33NO8: C, 61.18; H,
7.37; N, 3.10. Found: C, 61.46; H, 7.49; N, 2.98.
3.6. Benzyl (2,2-dimethoxyethyl)((3aS,4R,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (16α) and Benzyl (2,2-dimethoxyethyl)((3aS,4S,6R,6aS)-6-
((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (16β)
The crude hemiaminal coupling intermediate, prepared from 2,3:5,6-O-di-isopropylidene-D-
mannose (10, 107 mg, 0.41 mmol) as reported for 11α/11β, and NaHCO3 (70 mg, 0.82 mmol) were
dissolved in a mixture of H2O (4 mL) and EtOAc (2 mL), then Cbz-Cl (68 µL, 0.48 mmol) in EtOAc
(2 mL) was added dropwise at 0 ◦C. The mixture was allowed to reach room temperature and was left
stirring overnight under a nitrogen atmosphere. Successively, the mixture was washed with aqueous
1N HCl and brine. The organic phase was dried over anhydrous Na2SO4 and concentrated under
reduced pressure. After solvent evaporation, the crude oil was purified by flash chromatography
(EtOAc/Pet. ether = 1:3; Rf 16β = 0.55, Rf 16α = 0.42), thus affording compound 16β (43 mg, 0.09 mmol,
22%) and compound 16α (99 mg, 0.21 mmol, 50%), both as colorless oils.
16α: (α]23D = +45.9 (c 0.9, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.35 (s, 5H), 5.11
(br s, 5H), 4.69 (s, 0.5H), 4.42–4.31 (m, 2.5H), 4.07–4.00 (m, 1H), 3.89 (br s, 0.5H), 3.80–3.78 (m, 0.5H),
3.69 (br s, 1H), 3.36–3.33 (m, 7H), 1.49–1.43 (m, 6H), 1.36–1.32 (m, 6H). 13C-NMR (50 MHz, CDCl3)
mixture of rotamers: δ 155.7 (s), 135.9 (s), 129.0 and 128.9 (d), 128.8 and 128.6 (d, 2C), 128.2 and 128.1 (d,
2C), 112.6 and 112.4 (s), 108.9 (s), 103.8 and 103.7 (d), 96.7 and 96.6 (d), 85.8 (d), 84.3 (d), 82.1 and 81.5
(d), 74.0 and 71.2 (d), 67.9 and 66.6 (t), 64.6 (t), 55.1 and 55.0 (q, 2C), 50.6 (t), 26.8 (q), 26.2 (q), 25.3 (q),
24.4 (q). MS (ESI) m/z (%): 504.08 [(M + Na)+, 100]. IR (CDCl3): ν = 3453, 2940, 1709, 1383, 1211 cm−1.
Anal. Calcd. for C24H35NO9: C, 59.86; H, 7.33; N, 2.91. Found: C, 60.12; H, 7.41; N, 2.84.
16β: (α]23D = +8.0 (c 0.8, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.31–7.29 (m,
5H), 5.61 and 5.45 (s, 1H), 5.14–5.07 (m, 2H), 4.71–4.64 (m, 2H), 4.39–4.29 (m, 2.5H), 4.06–3.78 (m, 3H),
3.61–3.42 (m, 1.5H), 3.30–3.18 (m, 3H), 3.23 (s, 3H), 1.43–1.21 (m, 12H). 13C-NMR (50 MHz, CDCl3)
mixture of rotamers: δ 155.2 (s), 135.7 (s), 130.5 (d), 128.6 and 128.4 (d, 2C), 128.1 and 127.2 (d, 2C),
113.3 (s), 109.3 and 108.4 (s), 85.5 and 85.4 (d), 79.9 (d), 79.7 and 79.6 (d), 78.4 (d), 72.9 (d), 69.9 and 69.8
(d), 68.2 (t), 66.9 and 66.8 (t), 64.3 (t), 52.7 and 52.6 (q), 52.5 (q), 30.8 and 29.7 (q), 28.4 (q), 26.9 (q), 26.3
Molecules 2016, 21, 1405 12 of 18
and 25.1 (q). MS (ESI) m/z (%): 504.08 [(M + Na)+, 100]. IR (CDCl3): ν = 3456, 2985, 1703, 1261 cm−1.
Anal. Calcd. for C24H35NO9: C, 59.86; H, 7.33; N, 2.91. Found: C, 60.16; H, 7.44; N, 2.81.
3.7. (2R,4aS,6R,7R,7aR)-(9H-Fluoren-9-yl)methyl 7-hydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-
furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (17)
Compound 11α (134 mg, 0.27 mmol) was dissolved in trifluoroacetic acid (1 mL) and MeOH
(100 µL) and stirred at room temperature for 2 h. After TFA evaporation, the crude powder was
purified by flash chromatography (EtOAc/Pet. ether = 1:1; Rf 17 = 0.40), thus affording compound 17
as a white foam (62 mg, 0.15 mmol, 55%). (α]19D = +52.9 (c 0.09, CHCl3).
1H-NMR (400 MHz, CDCl3)
mixture of rotamers: δ 7.69 (d, J = 7.5 Hz, 2H), 7.50 (pt, J = 6.9 Hz, 2H), 7.33 (pt, J = 7.5 Hz, 2H), 7.26–7.22
(m, 2H), 5.13 and 4.57 (s, 1H), 4.74 (d, J = 3.9 Hz, 1H), 4.77–4.74 and 4.62–4.57 (m, 1H), 4.41–4.36 (m,
1H), 4.20 (t, J = 7.4 Hz, 1H), 4.21–4.15 (m, 1H), 4.05–3.96 (m, 2H), 3.86–3.77 (m, 1H), 3.67–3.65 (br s,
1H), 3.59–3.46 (m, 1.5H), 3.38 and 3.32 (s, 3H), 3.41–3.27 (m, 0.5H), 2.31 (br s, 2H). 13C-NMR (50 MHz,
CDCl3) mixture of rotamers: δ 155.4 (s), 143.9 and 143.7 (s, 2C), 141.4 (s, 2C), 127.8 (d, 2C), 127.1 (d, 2C),
125.0 (d, 2C), 120.0 (d, 2C), 95.6 and 95.5 (d), 78.8 (d), 73.0 (t), 69.0 (t), 68.5 and 68.4 (t), 67.7 (d), 66.6
(d), 55.0 and 54.9 (q), 47.1 (d), 42.4 and 42.3 (t). MS (ESI) m/z (%): 449.49 [(M + Na)+, 100]. IR (CDCl3):
ν = 3608, 3157, 1474, 1382, 1216 cm−1. Anal. Calcd. for C23H25NO7: C, 64.63; H, 5.90; N, 3.28. Found:
C, 64.80; H, 5.97; N, 3.21.
3.8. (2R,4aR,6R,7S,7aS)-(9H-Fluoren-9-yl)methyl 7-hydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-
furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (18)
Compound 12β (250 mg, 0.50 mmol) was dissolved in trifluoroacetic acid (1 mL) and MeOH
(100 µL) and stirred at room temperature for 2 h. After TFA evaporation, the crude powder was
purified by flash chromatography (EtOAc/Pet. ether = 1:1; Rf 18 = 0.43), thus affording compound 18
as a white foam (142 mg, 0.33 mmol, 66%). With the same procedure, compound 18 (153 mg, 0.36 mmol,
68%) was obtained also from the diastereomer 12α (264 mg, 0.53 mmol). (α]19D = −51.1 (c 1.2, CHCl3).
1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.70 (d, J = 7.5 Hz, 2H), 7.51 (pt, J = 6.6 Hz, 2H),
7.34 (pt, J = 7.3 Hz, 2H), 7.25 (pt, J = 6.9 Hz, 2H), 5.21 and 4.82 (s, 1H), 4.72 (d, J = 8.9 Hz, 1H), 4.59–4.56
(m, 1H), 4.42–4.13 (m, 2H), 3.99–3.76 (m, 3H), 3.54–3.39 (m, 2H), 3.38 and 3.32 (s, 3H), 3.26–3.19 (m,
1H), 3.02 (pt, J = 10.1 Hz, 1H), 2.24 (br s, 2H). 13C-NMR (100 MHz, CDCl3) mixture of rotamers: δ 156.0
(s), 143.8 (s, 2C), 141.3 (s, 2C), 127.8 (d, 2C), 127.1 (d, 2C), 125.0 (d, 2C), 120.0 (d, 2C), 95.0 (d), 78.8 (d),
73.9 (t), 68.3 (t), 67.7 (t), 66.6 (d), 66.0 (d), 55.0 (q), 47.1 and 46.7 (d), 42.6 and 41.5 (t). MS (ESI) m/z (%):
450.24 [(M + Na)+, 100], 876.66 [(2M + Na)+, 60]. IR (CDCl3): ν = 3610, 3155, 1472, 1382, 1216 cm−1.
Anal. Calcd. for C23H25NO7: C, 64.63; H, 5.90; N, 3.28. Found: C, 64.87; H, 5.99; N, 3.22.
3.9. (2R,4aR,7S,7aS)-(9H-Fluoren-9-yl)methyl 7-hydroxy-2-methoxytetrahydro-2H-
furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (19)
Compound 13α (203 mg, 0.43 mmol) was dissolved in trifluoroacetic acid (1 mL) and MeOH
(100 µL) and stirred at room temperature for 2 h. After TFA evaporation, the crude powder was
purified by flash chromatography (EtOAc/Pet. ether = 1:1; Rf 19 = 0.32), thus affording compound 19
as a white foam (80 mg, 0.20 mmol, 47%). (α]19D = −56.7 (c 1.0, CHCl3). 1H-NMR (400 MHz, CDCl3)
mixture of rotamers: δ 7.68 (d, J = 7.5 Hz, 2H), 7.52–7.50 (m, 2H), 7.34–7.21 (m, 4H), 5.70 and 5.60 (s,
1H), 4.76 (d, J = 8.9 Hz, 1H), 4.48–4.18 (m, 4H), 4.07–4.01 (m, 2H), 3.68 (pt, J = 14.6 Hz, 1H), 3.72 (dd,
J = 16.6 Hz, 8.6 Hz, 2H), 3.40 and 3.32 (s, 3H), 3.28–3.21 (m, 1H). 13C-NMR (100 MHz, CDCl3) mixture
of rotamers: δ 155.8 (s), 143.8 and 143.6 (s, 2C), 141.3 and 141.2 (s, 2C), 127.7 (d, 2C), 127.1 (d, 2C), 125.2
and 125.0 (d, 2C), 119.9 (d, 2C), 95.3 and 94.9 (d), 81.2 and 80.8 (d), 71.8 (t), 71.6 (d), 68.2 (t), 66.5 and
66.1 (d), 55.3 and 54.5 (q), 47.0 (d), 42.2 and 41.7 (t). MS (ESI) m/z (%): 420.35 [(M + Na)+, 100]. IR
(CDCl3): ν = 3619, 3020, 1714, 1451, 1221 cm−1. Anal. Calcd. for C22H23NO6: C, 66.49; H, 5.83; N, 3.52.
Found: C, 67.01; H, 5.90; N, 3.40.
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3.10. (2R,4aR,6R,7S,7aS)-Benzyl 6-((R)-1,2-dihydroxyethyl)-7-hydroxy-2-methoxytetrahydro-2H-
furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (20)
Compound 16α (40 mg, 0.08 mmol) was dissolved in trifluoroacetic acid (1 mL) and stirred
at room temperature for 2 h. After TFA evaporation, the crude powder was purified by flash
chromatography (EtOAc, Rf 20 = 0.19), thus affording compound 20 as white foam (19 mg, 0.05 mmol,
65%). (α]23D = −51.6 (c 0.5, CHCl3). 1H-NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.28 (s, 5H),
5.29 and 5.16 (s, 1H), 5.15–5.08 (m, 2H), 4.73 and 4.64 (s, 1H), 4.10 (s, 1H), 3.82–3.58 (m, 5H), 3.47–3.44
(m, 1H), 3.32 (s, 3H), 3.33–3.26 (m, 1.5H), 3.10–3.07 (m, 0.5H), 2.43 br s, 3H, OH). 13C-NMR (100 MHz,
CDCl3) mixture of rotamers: δ 155.5 (s), 136.0 (s), 128.6 (d, 2C), 128.3 (d, 2C), 128.0 (d), 96.0 and 95.5
(d), 73.6 (d), 69.9 (d), 68.93 (d), 68.90 (d), 67.9 (t), 66.6 and 66.2 (t), 62.7 and 62.6 (d), 54.9 (q), 42.7 and
42.6 (t). MS (ESI) m/z (%): 392.05 [(M + Na)+, 100]. IR (CDCl3): ν = 3628, 3618, 3020, 1793, 1472, 1384,
1216 cm−1. Anal. Calcd. for C17H23NO8: C, 55.28; H, 6.28; N, 3.79. Found: C, 55.98; H, 6.40; N, 3.70.
3.11. (R)-1-((2R,4aR,6R,7S,7aS)-7-Hydroxy-2-methoxy-4-tosylhexahydro-2H-
furo[3,2-b][1,4]oxazin-6-yl)ethane-1,2-diol (23)
To a solution of 22 [22] (45 mg, 0.14 mmol) and DIPEA (50 µL, 0.28 mmol) in dry CH2Cl2 (2 mL),
a solution of TsCl (54 mg, 0.09 mmol) in dry CH2Cl2 (2 mL) was added slowly at 0 ◦C. The mixture
was allowed to reach room temperature and was left stirring under a nitrogen atmosphere for 24 h.
Then, water was added slowly and the resulting mixture was washed with a saturated solution of
NaHCO3 and brine. The organic phase was dried over anhydrous Na2SO4 and concentrated under
reduced pressure. The crude compound was left stirring in MeOH (2 mL) in presence of a catalytic
amount of Ambersep 900 OH at room temperature for 1 h. The resin was then filtered and, after
solvent evaporation, the crude mixture was purified by flash chromatography (EtOAc/Pet. ether = 1:1;
Rf 23 = 0.19) thus affording pure compound 23 (23 mg, 0.06 mmol, 41%) as a white foam. (α]
19
D = −41.7
(c 0.6, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.2 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 5.15
(s, 1H), 4.75 (s, 1H), 4.21 (d, J = 4.5 Hz, 1H), 3.72 (dd, J = 11.8, 3.5 Hz, 1H), 3.61 (dd, J = 9.7, 3.4 Hz,
1H), 3.56–3.50 (m, 3H), 3.39 (s, 3H), 3.31–3.27 (m, 1H), 3.08 (dd, J = 11.8, 2.6 Hz, 1H), 2.41 (s, 3H), 1.99
(br s, 3H, OH). 13C-NMR (50 MHz, CDCl3): δ 143.2 (s, 2C), 134.7 (s, 2C), 128.4 (d, 2C), 127.0 (d, 2C),
94.4 (d), 78.1 (d), 75.3 (d), 72.5 (d), 67.7 (d), 66.4 (d), 61.6 (t), 54.1 (q), 42.2 (t), 28.7 (q). MS (ESI) m/z
(%): 412.23 [(M + Na)+, 100]. IR (CDCl3): ν = 3618, 3054, 1472, 1354, 1218, 1174 cm−1. Anal. Calcd. for
C16H23NO8S: C, 49.35; H, 5.95; N, 3.60. Found: C, 49.91; H, 6.04; N, 3.48.
3.12. Cell Culture
Human MDA-MB-231 breast cancer cell lines are a model for aggressive, hormone-independent
breast cancer. Cells were obtained from the American Tissue Culture Collection (Manassas, VA,
USA) and maintained in DMEM (from Life Technologies, Carlsbad, CA, USA) containing 10% heat
inactivated fetal calf serum (FCS, from Life Technologies) at 37 ◦C in a humidified atmosphere of 5%
CO2 /95% air. Cells were harvested from subconfluent cultures by incubation with a trypsin–EDTA
solution, and propagated every 3 days at a ratio between 1:4 and 1:8.
3.13. Cell Growth Assay
MDA-MB-231 cells were plated at 5 × 104 cells/mL in 24-well plates under standard culture
conditions. After 4h adhesion, cells were treated with either vehicle alone or different compounds.
After 24 h or 48 h of treatments, cells were trypsinized, collected, and counted using a hemocytometer.
3.14. Cell Viability
Cell viability assay was performed using the WST-1 assay, a tetrazolium salt analog to MTT or
XTT. Briefly, MDA-MB-231 cells were plated in in triplicate in a 96-well at 10–15× 103 cells/mL density.
After 4 h adhesion, cells were treated with different concentration of compound 1. Following 24 h or
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48 h incubation, cells were exposed to 10 µL of the reagent directly to the cell cultures (200 µL final
volume). The plates were incubated for 120 minutes at 37 ◦C in a humidified 5% CO2 environment.
The WST-1 formazan product was measured at 460 nm (reference wavelength of 630 nm) with an
ELx800 Universal Microplate Reader from Bio-Tek Instruments Inc. (Winooski, VT, USA).
3.15. Cell Cycle Analysis
MDA-MB231 cells were plated at 5 × 105 cells/mL in 6-well plates under standard culture
conditions. After 4 h adhesion, cells were treated with different concentration of compound 1. After 48 h
cells were harvested by trypsinization, and then permeabilized with 70% ice-cold ethanol on ice for
30 min. Cells were then washed and incubated in staining buffer with 50 µg/mL propidium iodide
(PI), 10 µg/mL RNase A and 0.1% Triton X-100 for 30 min in the dark. Subsequently, the cell cycle was
analyzed by flow cytometry (FACSCan; BD Biosciences, San Jose, CA, USA).
3.16. Data Analysis
The results are expressed as mean± standard deviation (SD). Differences in growth rates between
groups were analyzed using the two-tailed t-test, statistical significance at p-values <0.05 were
presented using respective symbols in the figure legends.
4. Conclusions
In recent years, small molecules drug discovery and development became a highly challenging
field, and in this view we have identified potential novel drug compounds starting from library
compounds and investigated their effect on a malignant human tumor cell line. Specifically, the
application of a cell-based growth inhibition assay on a library of skeletally different glycomimetics
allowed for the selection of a novel chemotype based on the hexahydro-2H-furo[3,2-b][1,4]oxazine
scaffold as a hit inhibitor of MDA-MB-231 cell growth. Subsequent follow-up synthesis of parent
compounds and preliminary biological studies validated the selection of 1 as a valuable lead compound
for the modulation of breast carcinoma cell cycle mechanism.
Although follow-up compounds showed reduced activity as compared to 1, interesting
structure-activity analysis showed a quite specific structural requirement, revealing that both the
three hydroxyl group and the Fmoc group are crucial for inhibition. Compound 1 clearly induced a
significant arrest of MDA-MB-231 cell cycle, and we assume that the growth inhibition induced by
compound 1 on MDA-MB-231 cells might be correlated to a cytostatic effect, whereas no significative
effect on cell adhesion and apoptosis was found.
Although we have found a cytostatic effect on tumor cells, future experiments on non-transformed
epithelial cells will be performed to ensure the selectivity and specificity of the compounds [57].
The identification of the target responsible for the observed phenotype, above the many different
growth factor signals and cyclin-dependent kinases will shed light in the understanding of tumor
cell growth and progression [58,59]. Moreover, further investigations will be attempted in view to
characterize the signaling pathways underlying the biological effect [60–62], particularly investigating
the role of caspases and the modulation of their phosphorylation [60,63,64].
Further biological tests will be carried out starting from flow cytometry profiling and the use of
reverse chemical genetics approaches to have insight into more detailed fine mechanisms that regulate
the cell cycle [39,68,69].
Supplementary Materials: The following are available online at: http://www.mdpi.com/1420-3049/21/10/
1405/s1, copies of 1H- and 13C-NMR spectra of 11–20 and 23, and HPLC chromatograms for stability studies
of 18.
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